Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 27, 2015 8:45 PM ET


Company Overview of Sandoz International GmbH

Company Overview

Sandoz International GmbH develops, manufactures, and markets generic pharmaceutical products. The company offers oral solids, gels, patch technologies, inhalers, anti-infective medicines, antibiotics, cardiovascular medicines, treatments for central nervous system disorders, gastrointestinal medicines, and oncology and respiratory therapies; medications for blood and blood forming organ disorders; and injectables including liquid vials, lyophilized vials, powder for oral suspensions, and pre-filled syringes. It also offers biopharmaceuticals such as biosimilars; oncology injectables; pharmaceutical intermediates, active pharmaceutical ingredients, and finished dosage forms; medicines for va...

Industriestrasse 25

Holzkirchen,  83607



49 8024 476 0


49 8024 476 2599

Key Executives for Sandoz International GmbH

Global Head
Age: 40
Chief Financial Officer
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Head of Western Europe, Middle-East & Africa
Compensation as of Fiscal Year 2014.

Sandoz International GmbH Key Developments

BioQuiddity Incorporated Signs Licensing Agreement with Sandoz International GmbH

BioQuiddity Incorporated has signed an exclusive licensing and supply agreement with Sandoz International GmbH under which Sandoz has the right to market BioQuiddity's ready-to-use ropivacaine and propofol infusion pharmaceutical products in the US. Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit-dose infusion systems, and Sandoz is responsible for marketing and commercializing the products.

Sandoz International Gmbh Launches New Inhaler for Asthma and COPD in Portugal and Ireland

Sandoz International GmbH has launched AirFluSal Forspiro, a new inhaler for patients with asthma and/or chronic obstructive pulmonary disease, or COPD, in Portugal and Ireland. AirFluSal offers the proven combination of salmeterol and fluticasone propionate in an innovative new device. It was developed at Aeropharm GmbH in Rudolstadt, Germany, Sandoz's global respiratory Center of Excellence.

Sandoz Announces US Market Introduction of Tobramycin Inhalation Solution, USP, Generic Version of TOBI

Sandoz announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation 1. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa. Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 worldwide) have cystic fibrosis2. Sandoz is marketing tobramycin inhalation solution, USP in 300 mg/5 mL single-dose ampules, the same size and strength that is currently marketed by the brand.

Similar Private Companies By Industry

Company Name Region
Prontomed GmbH Europe
MedInnova GmbH Europe
Myr Europe
Bayer Bitterfeld GmbH Europe
VIATRIS Holding GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sandoz International GmbH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at